On September 8, Amgen fell 5.08% in pre-market trading, trading at approximately 414.54 USD/share, with turnover of 174,400 USD. The decline was triggered by the Phase III clinical trial failure of Novartis's potential blockbuster heart drug pelacarsen, which rattled confidence across the entire Lp(a)-targeting therapeutic space.

The pelacarsen trial enrolled 8,323 patients over a six-year follow-up period and was the world's first outcomes trial designed to verify whether lowering Lp(a) levels could reduce cardiovascular events. Its failure has raised significant market concerns about the commercial viability of the broader Lp(a) target class. Amgen is currently developing Olpasiran, a drug with a similar Lp(a)-lowering mechanism, and investors are now pricing in heightened clinical uncertainty for that program. Novartis shares fell over 7% in after-hours trading following the announcement, while Amgen dropped nearly 6% in sympathy.

Analysts have noted that the pelacarsen failure does not directly negate the scientific rationale that lowering Lp(a) may deliver cardiovascular benefits, but it has undeniably cast a negative shadow over the therapeutic pathway. This marks the second late-stage clinical setback for Novartis within a single week, compounding broader sector sentiment pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)